Goldman Sachs Group Inc Cti Biopharma Corp Transaction History

Goldman Sachs Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$4.2 - $6.01 $70,875 - $101,418	-16,875 Reduced 1.41%	1,183,198 $4.97 Million
Q1 2023 May 11, 2023	SELL	$4.2 - $6.01 $70,875 - $101,418	-16,875 Reduced 1.41%	1,183,198 $4.97 Million
Q4 2022 May 14, 2024	SELL	$4.45 - $6.17 $1.49 Million - $2.07 Million	-335,471 Reduced 21.85%	1,200,073 $7.21 Million
Q4 2022 Feb 13, 2023	SELL	$4.45 - $6.17 $1.49 Million - $2.07 Million	-335,471 Reduced 21.85%	1,200,073 $7.21 Million
Q3 2022 May 14, 2024	BUY	$5.36 - $7.43 $4.76 Million - $6.6 Million	887,948 Added 137.11%	1,535,544 $8.94 Million
Q3 2022 Nov 10, 2022	BUY	$5.36 - $7.43 $4.76 Million - $6.6 Million	887,948 Added 137.11%	1,535,544 $8.94 Million
Q2 2022 May 14, 2024	BUY	$3.55 - $6.27 $2.3 Million - $4.06 Million	647,596 New	647,596 $3.87 Million
Q2 2022 Aug 15, 2022	BUY	$3.55 - $6.27 $1.06 Million - $1.87 Million	298,421 Added 85.46%	647,596 $3.87 Million
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $547,443 - $1.51 Million	288,128 Added 471.98%	349,175 $1.63 Million
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.86 $87,907 - $174,594	61,047 New	61,047 $152,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.